Enhancement of antitumor vaccine in ablated hepatocellular carcinoma by high-intensity focused ultrasound

doi:10.3748/wjg.v16.i28.3584

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 28

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5492)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

427

HTML

4564

Figures (1-3)

289

Tables (1-4)

212

Sum=5492

Jul 28, 2010 (publication date) through Jan 12, 2025

Times Cited of This Article

Times Cited (41)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jul 28, 2010; 16(28): 3584-3591
Published online Jul 28, 2010. doi: 10.3748/wjg.v16.i28.3584

Table 1 Cytotoxicity rate of splenic lymphocytes against H22 and H16 tumor cells in the vaccinated and high-intensity focused ultrasound-treated mice (mean ± SD)

	Cytotoxicity rate (%)
	H22 tumor cells	B16 tumor cells
Control group	15.9 ± 3.6	13.5 ± 2.3
Tumor vaccine group	30.7 ± 2.7^d	14.1 ± 1.9
HIFU vaccine group	37.5 ± 4.5^a^d	13.8 ± 2.2
HIFU therapy group	62.7 ± 6.5^d^f	18.1 ± 3.9

^aP < 0.05 vs the tumor vaccine group;

^dP < 0.001 vs the control group;

^fP < 0.001 vs the HIFU vaccine and tumor vaccine groups. HIFU: High-intensity focused ultrasound.

Table 2 Tumor volume of the vaccinated and high-intensity focused ultrasound-treated mice after a subsequent H22 tumor challenge (mean ± SD)

	Average tumor volume (mm³) after H22 tumor challenge
	2 wk	3 wk	4 wk
Control group	343.3 ± 129.5	829.3 ± 316.4	1953.0 ± 848.2
Tumor vaccine group	504.1 ± 173.7	733.4 ± 301.3	1760.2 ± 1075.1
HIFU vaccine group	279.7 ± 117.2	382.8 ± 170.6^a^d	914.3 ± 474.2^a^d
HIFU therapy group	0	0	0

^aP < 0.05 vs the tumor vaccine group;

^dP < 0.01 vs the control group. HIFU: High-intensity focused ultrasound.

Table 3 CD86, CD80 and MHC-II expression by bone marrow-derived dendritic cells after incubation with high-intensity focused ultrasound- and tumor-generated vaccines (mean ± SD, %)

	CD86	CD80	MHC-II
Control group	2.05 ± 1.40	4.81 ± 1.56	3.04 ± 0.60
Tumor vaccine group	11.70 ± 0.85^b	13.50 ± 0.14^b	13.75 ± 0.59^b
HIFU vaccine group	14.65 ± 0.49^b	16.05 ± 0.50^b	15.90 ± 0.28^b

^bP < 0.001 vs the control. HIFU: High-intensity focused ultrasound.

Table 4 Interleukin-12 and interferon-γ secretion by bone marrow-derived dendritic cells after incubation with high-intensity focused ultrasound- and tumor-generated vaccines (mean ± SD)

	IL-12 (pg/mL)	IFN-γ (pg/mL)
Control group	80.2 ± 4.6	58.0 ± 0.9
Tumor vaccine group	206.8 ± 5.3^b	207.0 ± 3.4^b
HIFU vaccine group	264.7 ± 2.0^b	247.8 ± 9.0^b

^bP < 0.001 vs the control group. HIFU: High-intensity focused ultrasound; IL-12: Interleukin-12; IFN-γ: Interferon-γ.

Citation: Zhang Y, Deng J, Feng J, Wu F. Enhancement of antitumor vaccine in ablated hepatocellular carcinoma by high-intensity focused ultrasound. World J Gastroenterol 2010; 16(28): 3584-3591
URL: https://www.wjgnet.com/1007-9327/full/v16/i28/3584.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i28.3584